Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections

Kohei Hara, Shigeru Kohno, Yasumasa Dohtsu, Kotaro Oizumi, Akira Watanabe, Kaoru Shimada, Hajime Goto, Masataka Katsu, Toshio Fukui, Setsuko Kurishima, Hiroyuki Kobayashi, Hisashi Inoue, Jingoro Shimada, Takaya Shiba, Masanobu Kaji, Hiroichi Tanimoto, Kazuo Ohara, Koichiro Nakata, Yoshitaka Nakamori, Junzaburo KabeKohichiro Kudo, Isao Arioka, Shigeki Odagiri, Kaneo Suzuki, Kou Murohashi, Izumi Koyama, Osamu Sekine, Nobuki Aoki, Rinzo Soejima, Jiro Hino, Keizo Matsumoto, Toshiaki Yoshida, Naoto Rikitomi, Tsuyoshi Nagatake, Masakazu Takasugi, Masaru Nasu, Hideaki Shigeno, Jun Goto, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Nobuya Ogawa, Keizo Yamaguchi, Kazuyuki Sugawara

    Research output: Contribution to journalArticlepeer-review

    Abstract

    We carried out a dose finding comparative study using ceftazidime (CAZ) as a reference drug to determine the optimal dose of cefclidin (CFCL), a newer parenteral cephalosporin, in the treatment of chronic respiratory tract infections. As a rule CFCL was injected in a total dose of 2 g a day (1 g twice a day) or 4 g a day (2 g twice a day), and CAZ was injected in a total dose of 2 g a day (1 g twice a day) for 14 days. A total of 136 patients (CFCL 2 g group: 45 patients; CFCL 4 g group: 44 patients; CAZ group: 47 patients) were enrolled. Clinical efficacy and safety assessments were made in 124 patients (CFCL 2 g group: 39 patients; CFCL 4 g group: 41 patients; CAZ group: 44 patients) and 129 patients (CFCL 2 g group: 41 patients, CFCL 4 g group: 43 patients; CAZ group: 45 cases). These findings indicate that CFCL 2 g a day (1 g twice a day) and CFCL 4 g a day (2 g twice a day) are almost the same from the standpoint of overall clinical efficacy and safety. Based on these results, we concluded that CFCL 2 g a day was the optimal dosage in the treatment of chronic respiratory tract infections, including a P. aeruginosa infection, from the point of view of efficacy and safety.

    Original languageEnglish
    Pages (from-to)1057-1076
    Number of pages20
    JournalChemotherapy
    Volume40
    Issue number8
    DOIs
    Publication statusPublished - 1992 Aug

    Keywords

    • CAZ
    • Dose finding study
    • Respiratory tract infections (RTI)
    • cefclidin (CFCL, E 1040)

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Dose-finding comparative study on cefclidin in the treatment of chronic respiratory tract infections'. Together they form a unique fingerprint.

    Cite this